Systematic review: Impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares

Alimentary Pharmacology and Therapeutics

Volumn 29, Issue 3, 2009, Pages 247-257

  Higgins, P D R ^a   Rubin, D T ^b   Kaulback, K ^c   Schoenfield, P S ^a,d   Kane, S V ^e  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^c Research in Practice   (Canada)

^d VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^e MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASAMAX; BALSALAZIDE; MESALAZINE; OLSALAZINE; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG;

COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DISEASE ACTIVITY; HEALTH CARE COST; HUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; SYSTEMATIC REVIEW; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MESALAMINE; MIDDLE AGED; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; YOUNG ADULT;

EID: 58149094256     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03865.x     Document Type: Review

References (48)

1. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care 2004 27 : 1218 24.
2. Murphy DA, Sarr M, Durako SJ, Moscicki AB, Wilson CM, Muenz LR. Barriers to HAART adherence among human immunodeficiency virus-infected adolescents. Arch Pediatr Adolesc Med 2003 157 : 249 55.
3. Loghman-Adham M. Medication noncompliance in patients with chronic disease: issues in dialysis and renal transplantation. Am J Manag Care 2003 9 : 155 71.
4. Peura D. Helicobacter pylori: rational management options. Am J Med 1998 105 : 424 30.
5. DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care 2002 40 : 794 811.
6. WHO. Adherence to Long-Term Therapies. Evidence for Action [Internet], Vol. 2008. Geneva : World Health Organization, 2003.
7. Rudd P. Clinicians and patients with hypertension: unsettled issues about compliance. Am Heart J 1995 130 : 572 9.
8. Morris A, Brennan G, MacDonald T, Donnan P. Population-based adherence to prescribed medication in type 2 diabetes: a cause for concern. Diabetes 2000 49 : A76.
9. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001 23 : 1296 310.
10. Ediger JP, Walker JR, Graff L, et al. Predictors of medication adherence in inflammatory bowel disease see comment Am J Gastroenterol 2007 102 : 1417 26.
11. Cerveny P, Bortlik M, Kubena A, Vlcek J, Lakatos PL, Lukas M. Nonadherence in inflammatory bowel disease: results of factor analysis. Inflamm Bowel Dis 2007 13 : 1244 9.
12. Lopez SR, Bermejo F, Carrera E, Perez-Abad M, Boixeda D. Adherence to treatment in inflammatory bowel disease. Rev Esp Enferm Dig 2005 97 : 249 57.
13. Shale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003 18 : 191 8.
14. Sewitch MJ, Abrahamowicz M, Barkun A, et al. Patient nonadherence to medication in inflammatory bowel disease see comment Am J Gastroenterol 2003 98 : 1535 44.
15. Bernal I, Domenech E, Garcia-Planella E, et al. Medication-taking behavior in a cohort of patients with inflammatory bowel disease. Dig Dis Sci 2006 51 : 2165 9.
16. Nigro G, Angelini G, Grosso SB, Caula G, Sategna-Guidetti C. Psychiatric predictors of noncompliance in inflammatory bowel disease: psychiatry and compliance. J Clin Gastroenterol 2001 32 : 66 8.
17. van Hees PA, van Tongeren JH. Compliance to therapy in patients on a maintenance dose of sulfasalazine. J Clin Gastroenterol 1982 4 : 333 6.
18. Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis [Review] [59 refs]. Aliment Pharmacol Ther 2006 23 : 577 85.
19. Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003 114 : 39 43.
20. Moody GA, Jayanthi V, Probert CS, Mac KH, Mayberry JF. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol 1996 8 : 1179 83.
21. Rubin DT, Lashner BA. Will a 5-ASA a day keep the cancer (and dysplasia) away? Am J Gastroenterol 2005 100 : 1354 6.
22. Rubin DT, Cruz-Correa MR, Gasche C, et al. Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update. Inflamm Bowel Dis 2008 14 : 265 74.
23. Velayos FS, Loftus EV Jr., Jess T, et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterology 2006 130 : 1941 9.
24. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 2005 100 : 1345 53.
25. Steiner JF, Koepsell TD, Fihn SD, Inui TS. A general method of compliance assessment using centralized pharmacy records. Description and validation. Med Care 1988 26 : 814 23.
26. Hall NJ, Rubin GP, Hungin APS, Dougall A. Medication beliefs among patients with inflammatory bowel disease who report low quality of life: a qualitative study. BMC Gastroenterol. 2007 7 : 20.
27. Loftus EV Jr. A practical perspective on ulcerative colitis: patients' needs from aminosalicylate therapies. Inflamm Bowel Dis 2006 12 : 1107 13.
28. Klugmann HJ, Giehler B, Lohmann D, Schiedewitz W. Individualized sulfasalazine treatment of ulcerative colitis and monitoring of patient compliance by determining sulfapyridine serum concentration [German]. Gastroenterol J 1990 49 : 160 4.
29. Bokemeyer B, Teml A, Roggel C, et al. Adherence to thiopurine treatment in out-patients with Crohn's disease. Aliment Pharmacol Ther 2007 26 : 217 25.
30. Cerveny P, Lukas M, Bortlik M, Kubena A, Vlcek J Non-adherence to medicamentuous treatment of inflammatory bowel disease and its most frequent forms. Cesk Gastroenterol Hepatol 2006 60 : 207 12 [Czech].
31. Bertomoro P, Vettorato M, Mazzocco K, Rumiati R, Sturniolo G, D'Inca R. Adherence to Medication in Inflammatory Bowel Disease Patients. Digestive Disease Week, Vol. 132. Washington, DC : American Gastroenterological Association, 2007 : A344.
32. Mackner LM, Crandall WV. Oral medication adherence in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2005 11 : 1006 12.
33. Oliva-Hemker MM, Abadom V, Cuffari C, Thompson RE. Nonadherence with thiopurine immunomodulator and mesalamine medications in children with Crohn disease. J Pediatr Gastroenterol Nutr 2007 44 : 180 4.
34. Waters BM, Jensen L, Fedorak RN. Effects of formal education for patients with inflammatory bowel disease: a randomized controlled trial. Can J Gastroenterol. 2005 19 : 235 44.
35. Kane S, Huo D, Magnanti K. A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clin Gastroenterol Hepatol 2003 1 : 170 3.
36. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet 1980 1 : 514.
37. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955 2 : 1041 8.
38. Kane S, Shaya F. Medication non-adherence is associated with increased medical health care costs. Dig Dis Sci 2008 53 : 1020 4.
39. Kane S, Shaya F, El-Khoury A. Poor compliance with 5-ASA therapy in patients with gastrointestinal disorders increases the burden on healthcare services: a retrospective survey in Maryland, USA. In : America CsaCFo, ed. Advances in IBD, Vol. 13. Miami, FL : Crohn's and Colitis Foundation of America, 2007 : 664.
40. Fendrick AM, Smith DG, Chernew ME, Shah SN. A benefit-based copay for prescription drugs: patient contribution based on total benefits, not drug acquisition cost. Am J Manag Care 2001 7 : 861 7.
41. Fendrick AM, Chernew ME. Value-based insurance design: a "clinically sensitive, fiscally responsible" approach to mitigate the adverse clinical effects of high-deductible consumer-directed health plans. J Gen Intern Med 2007 22 : 890 1.
42. Rosen AB, Hamel MB, Weinstein MC, Cutler DM, Fendrick AM, Vijan S. Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. Ann Intern Med 2005 143 : 89 99.
43. Levy RL, Feld AD. Increasing patient adherence to gastroenterology treatment and prevention regimens. Am J Gastroenterol 1999 94 : 1733 42.
44. Kane S. Medication adherence and the physician-patient relationship. Am J Gastroenterol 2002 97 : 1853.
45. Kripalani S, Yao X, Haynes RB. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med 2007 167 : 540 50.
46. Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990 150 : 1881 4.
47. Brun J. Patient compliance with once-daily and twice-daily oral formulations of 5-isosorbide mononitrate: a comparative study. J Int Med Res 1994 22 : 266 72.
48. Kardas P. The DIACOM study (effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of type 2 diabetes). Diabetes Obes Metab 2005 7 : 722 8.